| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-095 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于回购注销部分限制性股票通知债权人的公告 2、登记地点：湖南省长沙市高新区金洲大道 68 号 3、邮编：410000 4、联系人：证券投资部 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、通知债权人的原因 益丰大药房连锁股份有限公司（以下简称"公司"）于 2025 年 9 月 30 日召 开的第五届董事会第二十二次会议，审议通过了《关于回购注销 2022 年限制 性股票激励计划部分限制性股票的议案》。根据公司《2022 年限制性股票激励 计划（修订版）》之"第十三章公司/激励对象发生异动的处理"之"激励对象 个人情况发生变化的处理"的规定，以及"第八章限制性股票的授予与解除限 售条件"之"限制性股票的解除限售条件"关于个人绩效考核要求的规定，鉴 于部分激励对象离职、降级或个人绩效考核不达标，公司将回购 ...

益丰大药房连锁股份有限公司 | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-096 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 关于预计触发"益丰转债"转股价格向下修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 可转债代码：113682 转债简称：益丰转债 转股价格：31.84 元/股 转股期：自发行结束之日（2024 年 3 月 8 日，T+4 日）满六个月后的第一 个交易日（2024 年 9 月 8 日）起至可转债到期日（2030 年 3 月 3 日）止（如遇 法定节假日或休息日延至其后的第 1 个工作日；顺延期间付息款项不另计息）。 风险提示：本次触发转股价格修正条件的期间从 2025 年 9 月 17 日起算，截 至 2025 年 9 月 30 日，益丰大药房连锁股份有限公司（以下简称"公司"、"本 公司"）股票已有 10 个交易日的收盘价低于当期转股价格的 85%，预计将触发 转股价格 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-094 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于回购注销 2022 年限制性股票激励计划 部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 限制性股票回购数量与价格： 回购数量：25,516 股，回购价格：14.43 元/股； 益丰大药房连锁股份有限公司（以下简称"公司"或"本公司"）于 2025 年 9 月 30 日召开的第五届董事会第二十二次会议审议通过了《关于回购注销 2022 年限制性股票激励计划部分限制性股票的议案》。根据公司《2022 年限制 性股票激励计划（修订版）》相关规定，对公司限制性股票激励计划部分激励对 象已获授但尚未解除限售的限制性股票进行回购注销。现将相关事项公告如下： 根据公司《2022 年限制性股票激励计划（修订版）》之"第十三章公司/激 励对象发生异动的处理"之"激励对象个人情况发 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-093 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 2022 年限制性股票激励计划预留授予第二个 解除限售期解除限售条件成就的公告 重要内容提示： ● 公司将在办理完毕相关解除限售申请手续后，股份上市流通前，发布限 制性股票解除限售暨股份上市公告。 2025 年 9 月 30 日，益丰大药房连锁股份有限公司（以下简称"公司"或"本 公司"）召开的第五届薪酬与考核委员会第三次会议与第五届董事会第二十二次 会议审议通过了《关于 2022 年限制性股票激励计划预留授予第二个解除限售期 解除限售条件成就的议案》，同意对 29 名激励对象的 196,838 股限制性股票进 行解锁，具体情况如下： 一、股权激励计划限制性股票批准及实施情况 （一）本激励计划已履行的程序 1、2022 年 8 月 19 日，公司召开的第四届董事 ...

湖南启元律师事务所 关于益丰大药房连锁股份有限公司 2022年限制性股票激励计划预留授予部分第二 期解除限售条件成就及回购注销部分限制性股 票相关事项的 法律意见书 二〇二五年九月 1 致：益丰大药房连锁股份有限公司 湖南启元律师事务所（以下简称"本所"）受益丰大药房连锁股份有限公司 （以下简称"益丰药房"或"公司"）委托，担任公司实施 2022 年限制性股票激 励计划项目专项法律顾问，根据《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《益丰大药房连锁股份有限公司章程》（以下简称"《公司章程》"）、 《益丰大药房连锁股份有限公司 2022 年限制性股票激励计划（修订版）》（以下 简称"《激励计划》"）等有关规定，就公司本次激励计划预留授予部分第二期 解除限售条件成就（以下简称"本次解除限售"）及回购注销部分限制性股票（以 下简称"本次回购注销"）相关事项出具本法律意见书。 本所仅就与本次解除限售及本次回购注销有关的中华人民共和国境内（以下 简称"中国境内"，为本法律意见书之目的，不包括香港特别行政区、澳门特别 行政区和台湾地区）法律问题发表法律意见，而不对有关会计、审计及资产评估 等专业事项发表 ...

Core Viewpoint - Yifeng Pharmacy Chain Co., Ltd. has approved the second unlock condition for its 2022 restricted stock incentive plan, allowing 29 individuals to unlock a total of 196,838 shares, representing 0.02% of the company's total share capital as of 2025 [1] Summary by Category Company Performance - The company's net profit for 2024 is projected to increase by 71.98% compared to 2021, indicating strong financial growth [1] - The performance assessment criteria have been met, with 29 incentive recipients achieving an annual assessment completion rate of 80% or above [1] Stock Incentive Plan - The meeting held on September 30, 2025, resulted in the approval of the unlocking of restricted stocks for the second phase of the incentive plan [1] - The company will issue an announcement regarding the unlocking of restricted stocks and the listing of shares before the completion of related procedures [1]

Core Viewpoint - The offline pharmacy industry is undergoing a significant transformation, shifting from rapid expansion to a focus on optimization and quality improvement, with many companies facing declining performance and store closures as a result of changing market dynamics and regulatory pressures [1][7]. Industry Performance - In the first half of 2025, several listed offline pharmacy companies reported weak performance, with major players like Yifeng Pharmacy, Lao Baixing, and Yixin Tang experiencing revenue declines [2]. - The retail pharmacy sector is seeing a slowdown in revenue growth, with some companies reporting negative growth for the first half of 2025, marking the end of a 20-year period of high growth [2][4]. Store Closures and Strategic Adjustments - Major pharmacy chains are closing stores to optimize their operations, with Yifeng Pharmacy closing 1,078 stores and Daclin closing 733 stores in 2024 [5]. - Guoda Pharmacy, once a member of the "10,000 store club," has closed over 1,270 stores as part of its strategic shift towards high-quality development, reducing its total store count from 10,702 to 9,569 by the end of 2024 [2][6]. Market Trends and Future Outlook - The overall retail pharmacy market is experiencing a contraction, with a significant decrease in the number of stores, dropping below 700,000 nationwide by the first quarter of 2025 [6]. - The industry is expected to undergo consolidation, with a shift from quantity expansion to quality improvement, driven by regulatory changes and market pressures [7][8]. - The rise of online pharmacy services is impacting traditional brick-and-mortar stores, but the latter are adapting by enhancing their service offerings and focusing on prescription drugs and health products [8].

Core Insights - The company held a performance briefing for the first half of 2025, emphasizing the stability of its main business segments: traditional Chinese medicine, Western medicine, and non-pharmaceutical products [1] - Following the release of the "Special Action Plan to Promote Healthy Consumption" by the state in April 2025, policies encouraging diversified development in pharmacies are expected to drive growth in related sectors [1] Company Strategy - The company has established a non-pharmaceutical innovation division focusing on product innovation in functional and non-functional foods and supplies, including medical beauty skincare, personal care, and household cleaning products [1] - As community health access points, pharmacies benefit from high consumer trust and low marginal operating costs, allowing the company to validate its market through mainstream branded products [1] - Future strategies will involve deepening product selection based on health dimensions, quality screening, and cost-performance strategies, along with gradually expanding self-owned brands [1] Industry Trends - According to third-party statistics, the number of pharmacies in China reached a critical point in 2024, leading to a decline in single-store sales and profitability [1] - The period from 2025 to 2026 is expected to see a normalization of both openings and closures of stores, with an acceleration in industry consolidation [1] - For leading chains, adapting to changes in the era and policies, along with digital transformation, supply chain optimization, and innovative service models for health management across online and offline channels, will be key competitive advantages [1]

Market Overview - On September 25, the pharmaceutical commercial sector declined by 1.06%, with HeFu China leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable stock performances include: - N Jianfa Zhi (301584) surged by 418.58% to a closing price of 36.56, with a trading volume of 419,500 shares and a transaction value of 1.477 billion [1] - Jia Shi Tang (002462) increased by 6.61% to 14.51, with a trading volume of 193,500 shares and a transaction value of 279 million [1] - HeFu China (603122) fell by 4.69% to 6.51, with a trading volume of 169,000 shares and a transaction value of 112 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 337 million from institutional investors, while retail investors experienced a net outflow of 591 million [2] - Key capital flows for selected stocks include: - N Jianfa Zhi (301584) had a net inflow of 45.716 million from institutional investors, accounting for 30.94% of its total [3] - Jia Shi Tang (002462) recorded a net inflow of 51.35 million from institutional investors, representing 18.43% [3] - HeFu China (603122) experienced a net outflow of 16.49 million from retail investors, which is -43.96% of its total [3]

Core Viewpoint - Yifeng Pharmacy's stock price has shown fluctuations, with a year-to-date increase of 5.76% but a recent decline of 2.67% over the past five trading days [2] Financial Performance - For the first half of 2025, Yifeng Pharmacy reported operating revenue of 11.722 billion yuan, a year-on-year decrease of 0.35%, while net profit attributable to shareholders increased by 10.32% to 880 million yuan [2] - Cumulative cash dividends since the company's A-share listing amount to 2.852 billion yuan, with 1.946 billion yuan distributed over the past three years [3] Stock Market Activity - As of September 25, Yifeng Pharmacy's stock price was 24.78 yuan per share, with a market capitalization of 30.044 billion yuan [1] - The stock experienced a trading volume of 73.2279 million yuan and a turnover rate of 0.24% on the same day [1] - The net inflow of main funds was 754,600 yuan, with significant buying and selling activity from large orders [1] Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 7.70% to 21,600, with an average of 56,081 circulating shares per shareholder, a decrease of 7.15% [2] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 237 million shares, a decrease of 35.3896 million shares from the previous period [3]